Found 416 hits.
|
575. |
Salameh, P., Gutsche, A., Aulenbacher, F., Buttgereit, T., Weller, K., Siebenhaar, F., and Maurer, M.+: Urticaria control test real-world performance: a post hoc analysis. Allergy 2024: 79; 229-232. IF: TBD (IF 2023: 12.60) |
|
575.a |
Gutsche, A., Salameh, P., Aulenbacher, F., Buttgereit, T., Weller, K., Siebenhaar, F., and Maurer, M.+: Reply to: Zhang et al.: Clinical applicability of the Urticaria Control Test in patients with chronic urticaria: further evidence from 622 adult and pediatric patients with different disease subtypes. Allergy 2024: 79; 265-267. |
o.575a
|
576. |
Maurer, M.+, Lumry, W. R., Li, H. H., Aygören-Pürsün, E., Busse, P. J., Jacobs, J., Nurse, C., Ahmed, M. A., Watt, M., Yu, M., and SPRING Investigators: Lanadelumab in patients 2 to less than 12 years old with hereditary angioedema: results from the phase 3 SPRING study. J. Allergy Clin. Immunol. Pract. 2024: 12; 201-2011. IF: TBD (IF 2023: 8.20) |
o.576
|
577. |
Mostmans, Y.+, Maurer, M., Richert, B., Smith, V., Melsens, K., De Maertelaer, V., Saidi, I., Corazzi, F., and Michel, O.: Chronic spontaneous urticaria: evidence of systemic microcirculatory changes. Clin. Transl. Allergy 2024: 14; e12335. IF: TBD (IF 2023: 4.60) |
o.577
|
214. |
Muñoz, M., Kocatürk, E., Maurer, M., and Kolkhir, P.+: Emerging therapeutics in chronic urticaria. Immunol. Allergy Clin. North. Am. 2024: 44; 517-541. IF: TBD (IF 2023: 2.70) |
r.214
|
215. |
Maurer, M.+, Pereira, M. P., and Kolkhir, P.: The definition, classification, and history of urticaria. Immunol. Allergy Clin. North. Am. 2024: 44; 407-419. IF: TBD (IF 2023: 2.70) |
r.215
|
578. |
Maurer, M.+, Ensina, L. F., Giménez-Arnau, A. M., Sussman, G., Hide, M., Saini, S., Grattan, C., Fomina, D., Rigopoulos, D., Berard, F., Canonica, G. W., Rockmann, H., Irani, C., Szepietowski, J. C., Leflein, J., Bernstein, J. A., Peter, J., Kulthanan, K., Godse, K., Ardusso, L., Ukhanova, O., Staubach, P., Sinclair, R., Gogate, S., Thomsen, S. F., Tanus, T., Ye, Y. M., Burciu, A., Barve, A., Modi, D., Scoryrev, E., Hua, E., Letzelter, K., Varanasi, V., Patekar, M., Severin, T., and Pearl-1 and PEARL2 trial investigators: Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials. Lancet 2024: 403; 147-159. IF: TBD (IF 2023: 98.40) |
o.578
|
216. |
Zuberbier, T.+, Ensina, L. F., Giménez-Arnau, A., Grattan, C., Kocatürk, E., Kulthanan, K., Kolkhir, P.*, and Maurer, M.*: Chronic urticaria: unmet needs, emerging drugs and new perspectives on personalized treatment. Lancet 2024: 404; 393-404. IF: TBD (IF 2023: 98.40) |
r.216
|
579. |
Maurer, M., Albuquerque, M., Boursiquot, J.-N., Dery, E., Giménez-Arnau, A., Godse, K., Guitiérrez, G., Kanani, A., Lacuesta, G., McCarthy, J., Nigen, S., and Winders, T.+: A patient charter for chronic urticaria. Adv. Ther. 2024: 41; 14-33. IF: TBD (IF 2023: 3.40) |
o.579
|
217. |
Muñoz, M., Kiefer, L. A., Pereira, M. P., Bizjak, M., and Maurer, M.+: New insights into chronic inducible urticaria. Curr. Allergy Asthma Rep. 2024: 24; 457-469. IF: TBD (IF 2023: 5.40) |
r.217